Ruthigen To Hold Fiscal 2014 Financial Results Conference Call On Monday, June 30, 2014 - KYTX CBS 19 Tyler Longview News Weather Sports

Ruthigen To Hold Fiscal 2014 Financial Results Conference Call On Monday, June 30, 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Ruthigen, Inc.

SANTA ROSA, Calif., June 24, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN) today announced that the financial results for its fiscal 2014, ended March 31, 2014, will be released after the U.S. markets close on June 30, 2014. The earnings release will be followed by a conference call at 1:30 p.m. PDT (4:30 p.m. EDT) on June 30, 2014, to discuss fiscal 2014 results.

Individuals interested in participating in the conference call may do so by dialing 1-877-870-4263 for domestic callers or 1-412-317-0790 for international callers. Those interested in listening to the conference call live via the internet may do so at http://www.videonewswire.com/event.asp?id=99848. Please log on approximately 30 minutes prior to the presentation in order to complete the registration process.

A telephone replay will be available for seven days following the conclusion of the call by dialing 877-344-7529 for domestic callers, or 412-317-0088 for international callers, and entering conference code 10048626. A webcast replay will be available on the site at http://www.videonewswire.com/event.asp?id=99848 for one year following the call.

About Ruthigen
Ruthigen is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications.  The Company's lead drug candidate, RUT58-60, is a broad spectrum anti-infective that Ruthigen is developing for the prevention and treatment of infection in surgical and trauma procedures.  The Company plans to initiate patient enrollment for its Phase 1/2 clinical trial for RUT58-60 in the United States as early as July 2014 and pending the successful completion of that trial Ruthigen plans to conduct pivotal clinical trials, the first of which it anticipates will be its planned Phase 2B trial and the second of which it anticipates will be its planned Phase 3 trial.  

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

CBS19, MYTX & KCEB
2211 ESE Loop 323
Tyler, TX 75701
Phone (903) 581-2211
Fax (903) 581-5769

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KYTX. All Rights Reserved. Users of this site agree to the Terms of Service, Privacy Notice/Your California Privacy Rights, and Ad Choices.